A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
← catalyst calendarSponsored by Praxis Precision Medicines (industry) · PRAX — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
77estimated
Sites
8
Countries
Israel, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-02 | actual | When the study began enrolling |
| Primary completion | 2025-11-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- SCN2A Encephalopathy
- SCN8A Encephalopathy
Intervention
- Drug: PRAX-562
Primary outcomes
what the primary-completion date above is the date OFPART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs
measured 16 weeks
PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs
measured 48 weeks
Permalink · PRAX's whole pipeline · Catalyst calendar · Every registered study · What changed